Targinta selects lead drug candidate for triple-negative breast cancer
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]
Xintela Half-year Report 2021-01-01 – 2021-06-30
Summary of the half-year report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 1 April – 30 June 2021 · Income amounted to TSEK 0 (0). · Loss before tax totalled TSEK 11,797 (loss: 9,087). · Loss per share* was SEK 0.13 (loss: 0.22). · At 30 June […]
Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE […]
Xintela intends to carry out a directed share issue through an accelerated book building procedure
Lund, 2021-06-16 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE […]
Xintela to develop stem cell therapy for difficult-to-heal wounds
Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with […]
Targinta recruits Per Norlén as CEO
Lund, Sweden, May 4, 2021 – Xintela announces today that Per Norlén has been recruited as CEO of Xintela’s wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela’s Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in […]
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
Lund, Sweden, 6 April 2021 – Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate the potential of the company’s stem cell product XSTEM® in the treatment of ARDS, a life-threatening lung complication that can affect severely ill COVID-19 […]
Xintela gets tissue establishment license
Lund, Sweden, 19 March 2021 – Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products. In order to conduct activities that use human tissues and cells for the manufacture of medicinal products, a tissue establishment license […]
Xintela gets patent grant in Europe for XSTEM stem cell product
Lund, Sweden, 17 March 2021 – Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company’s stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells. Xintela previously announced (October 29, 2020) the preliminary approval of its European patent application from the EPO for the XSTEM stem […]
Xintela publishes results from glioblastoma antibody study
Lund, Sweden, March 12, 2021 – Xintela announces that the results of the company’s preclinical glioblastoma study with function-blocking antibodies have today been published in the renowned international scientific journal Cancers. The publication shows, among other things, that antibodies directed to the company’s target molecule integrin 101 significantly reduce the growth of the aggressive and […]
